Puma Biotechnology, Inc.
PBYIHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframePuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. Valued at $362.4M, PBYI is a small-cap name in its sector. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Market Cap
$362.4M
Beta
1.23
P/E (TTM)
14.83
P/E (Fwd)
20.34
EPS (TTM)
$0.48
EPS (Fwd)
$0.35
ROE
21.6%
ROA
9.5%
Cash
$101.5M
Total Debt
$16.0M
Free CF
$44.1M
52W Change
114.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $101.5M in cash comfortably exceeding the $16.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $44.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 21.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $228.0M (2022) to $228.4M (2025).
With cash comfortably exceeding debt, PBYI has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PBYI.